Navigation Links
CEL-SCI Corporation Announces 2007 Financial Results
Date:1/14/2008

As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

CEL-SCI CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

YEARS ENDED SEPTEMBER 30, 2007 and 2006

2007 2006

GRANT REVENUE AND OTHER $ 57,043 $ 125,457

OPERATING EXPENSES:

Research and development (excluding

R&D depreciation of $91,292, $74,043

and $96,442 respectively, included

below) 2,528,528 1,896,976

Depreciation and amortization 176,186 170,903

General & administrative 6,704,538 3,406,774


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
3. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
8. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
9. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
(Date:8/1/2015)... ... , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was ... National Retail Federation, the largest retail trade association in the world, for her “advocacy ... to be named as such. According to the NRF’s website, Retail Champions are “Main ...
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... an important workshop at its new True North Conference Center. The medical community, ... that the Jacksonville community may be more aligned in the effort to better ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... in Canadian hospitals, way beyond estimation, raising concern among ... investigator in the study said, “The stark reality in ... and other drug-resistant bacteria are posing a serious threat ... these super bugs are more likely to have longer ...
... a drug charity has revealed that young men are ... looks as well as to boost their self-confidence.// ... body builders and athletes to improve their performance, were ... building site workers between the ages 16 and 25. ...
... been developed by a researcher from Cornell University that detects ... in food processing.// , ‘It’s very inexpensive, it ... and it could be activated for whatever you want to ... Professor of Fibre Science and Apparel Design at Cornell. ...
... next week the distribution of a drug to help fight ... Africa is being affected by an extremely virulent strain of ... in the country. The health officials have now promised that ... next week to help fight the disease. The officials but ...
... properly for their safety and efficacy, says a ... // The drugs that are being indiscriminately prescribed ... ,The researchers analyzed drugs covered by a "congressionally ... the Food and Drug Administration (FDA) may extend ...
... branded inhalation capsules in India for the treatment of ... Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, ... 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending ... product is to be used only with the Rheohaler ...
Cached Medicine News:Health News:Nanotech Wipes for biohazard detection 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 3
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Medicine Products: